Post-stroke Mood and Emotional Disturbances: Pharmacological Therapy Based on Mechanisms

Jong S. Kim
Department of Neurology, University of Ulsan, Asan Medical Center, Seoul, Korea

Introduction

Mood and emotional disturbances are frequent symptoms in stroke survivors. These symptoms are distressing for both the patients and their caregivers, and negatively influence patient quality of life. Important mood/emotional disturbances include post-stroke depression (PSD), post-stroke anxiety, post-stroke emotional incontinence (PSEI), post-stroke anger proneness (PSAP), and post-stroke fatigue (PSF). Underlying factors and predictors of these emotional disturbances partially overlap, but are still different. The relationships between these phenomena and lesion locations differ when considering the different emotional symptoms. Thus, these diverse emotional disturbances are pathophysiological interrelated, but are different phenomena. Studies have shown that these emotional disturbances have negative impacts on patients’ clinical outcomes. PSD, for example, negatively influences later functional outcomes after stroke, decreases quality of life, leads to less efficient use of rehabilitation services, and increases mortality. Patients with PSF are more often unemployed, change their jobs, and fail to return to previous jobs than those without PSF. Although the overall negative impacts of PSEI and PSAP are less marked than those of PSD, they still lead to distress and embarrassment, impair certain domains of patients’ quality of life, and increase

Keywords Stroke; Depression; Emotion; Serotonin; Treatment

Copyright © 2016 Korean Stroke Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
caregiver burden.\textsuperscript{17}

Fortunately, these mood and emotional disturbances can be treated or prevented by various methods, including pharmacological therapy. In order to administer the proper therapy, we have to understand the similarities and differences between the phenomenologies and pathophysiological mechanisms associated with these symptoms. Regrettably, these important symptoms have been underdiagnosed, neglected, and under-studied.

This narrative review will describe some of the most common or relevant post-stroke mood and emotional disturbances. The phenomenology, underlying factors or predictors, and relevant lesion locations will be described. I will also discuss pharmacological treatments for these emotional disturbances based on presumable pathophysiological mechanisms.

### Depression and depressive mood

#### Symptom characteristics and prevalence

The symptoms of post-stroke depression or depressive symptoms include depressed mood, anhedonia, loss of energy, decreased concentration, and psychic retardation. Although somatic symptoms, such as decreased appetite and insomnia are common, they may in part be attributed to the stroke itself, medications, or comorbid diseases. Guilty feelings and suicidal ideations are less common than observed in primary depression.\textsuperscript{18}

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition has been used for the diagnosis of PSD. It defines depression as depressed mood or anhedonia (loss of interest or pleasure) for 2 weeks or longer, in addition to the presence of at least four of the following symptoms: substantial weight loss or gain, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, worthlessness or inappropriate guilt, diminished concentration, and indecisiveness. However, it remains controversial whether these criteria, validated in physically intact persons, can be used in stroke patients, especially in the acute setting. Thus, other interviewer-administered or self-completed depression case-finding or screening instruments are also used in the study of PSD. These include the nine-item Patient Health Questionnaire, The Center of Epidemiological Studies-Depression Scale, Hospital Anxiety and Depression Scale, the Hamilton Depression Rating Scale, the Beck Depression Inventory, and the Montgomery-Asberg Depression Scale.\textsuperscript{19}

The prevalence of PSD ranges from 5 to 67%.\textsuperscript{1,20-25} The wide variability is due to different study settings, time since stroke, and the different criteria/methods used to diagnose PSD.\textsuperscript{26} A meta-analysis of 61 cohorts involving 25,488 patients published in 2014 indicated that 31% of patients developed depression at some time point up to 5 years following stroke.\textsuperscript{27} Generally, the prevalence of major depression decreases over time. In one study, PSD was present in 50% of the patients in the acute phase, but only in 12% of the patients at a one-year follow-up.\textsuperscript{28} Another study reported the prevalence of depression as 30% at 3 months post-stroke. Of these patients, 60% were no longer depressed one year later.\textsuperscript{29} In the author’s recent study involving 478 patients with acute stroke, approximately 57% had depression (Montgomery-Asberg Depression Scale > 8) at the time of the stroke. This percentage rapidly decreased over time.\textsuperscript{30}

#### Factors associated with PSD

Although various factors have been reported to be associated with PSD, the results have been inconsistent. A recent systematic review included 23 studies with 18,374 participants, and reported that demographic characteristics (age and sex) were not consistently associated with PSD.\textsuperscript{31} There was also no consistent association between hemisphere of stroke, lesion location, or pathological subtype, and depression. A history of depression before stroke was associated with PSD in four of seven studies, while cognitive impairment was associated with depression in two of four studies.

Based on the literature, the most consistent factors associated with PSD are severe stroke, and early or late physical disability. In our recent study, changes in Montgomery-Asberg Depression Scale scores were well-correlated with improvements in neurological impairment.\textsuperscript{32} It seems that patients’ acute depressive symptoms are related to physical dysfunction, while PSD at the chronic stage has an additional psychosocial component.\textsuperscript{33}

#### Lesion location

Robinson emphasized the role of left frontal lesions in producing PSD.\textsuperscript{28} However, other studies have shown heterogeneous results,\textsuperscript{25,33-35} and one systematic review failed to find an association between lesion location and PSD.\textsuperscript{36} We have shown that frontolenticulocapsular-brainstem base lesions are related to PSD.\textsuperscript{37} An important confounding factor in these studies is the variability in time since stroke.\textsuperscript{37} One study found that the association between left anterior cortical stroke and PSD was apparent at the acute stage, but not the subacute or chronic stages.\textsuperscript{38} Higher lesion volumes, cerebral atrophy, silent infarcts, and white matter lesions may also be associated with a higher risk of PSD.\textsuperscript{39,40}

#### Pathophysiology

The close relationship between PSD and neurological deficits,\textsuperscript{1} and between changes in Montgomery-Asberg Depression Scale scores and neurologic improvement,\textsuperscript{40} suggests that PSD may be a psychological, reactive depressive symptom associated with sudden functional deficits. When there are prolonged functional...
deficits, subsequent familial and social issues may perpetuate PSD. The presence of PSD may also be dependent on the patients’ personality traits and environmental factors, such as social support, economic matters, job stability, etc.

However, there still are patients whose depression is not readily explained by neurological changes. For instance, patients with transient ischemic attacks or minor strokes can still have PSD. The possible role of anterior frontal lobe damage and the involvement of the frontal-basal ganglia brainstem pathway in PSD development suggest alterations in neurotransmitter systems, such as serotonergic, adrenergic, and dopaminergic systems. It is generally likely that patients with PSD have symptoms due to mixed mechanisms.

Treatment
In 2008, two Cochrane reviews were published regarding the prevention and treatment of PSD. The authors identified 14 prevention trials involving 1,515 people, and reported a small effect for psychological intervention. However, there was no evidence of an effect due to antidepressant drugs. Nevertheless, a few trials of antidepressant drugs published afterwards have shown some benefit of antidepressant drug use. The Cochrane review of treatment trials identified 16 trials involving 1,655 subjects. Although antidepressant drugs (13 trials) produced improvements in depressive symptoms, it is uncertain whether they lead to higher rates of remission for depression. The use of antidepressants increases gastrointestinal and central nervous system side effects. There was no evidence for effectiveness of psychological therapies alone for the treatment of PSD.

Therefore, although antidepressants seem to be effective for the treatment of PSD, the evidence is not robust. Nevertheless, European and American guidelines recommend pharmaceutical treatment, such as selective serotonin-reuptake inhibitors (SSRI) or tricyclic antidepressant drugs for patients with PSD, along with monitoring for effectiveness and side effects. It is recommended that treatment be continued for at least 6 months after initial recovery.

Post-stroke anxiety
Prevalence and characteristics
Post-stroke anxiety disorders have received relatively little attention compared to PSD. The core symptoms of post-stroke anxiety are excessive anxiousness or worry, and difficulty in controlling worries. Criteria from The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition require three or more of the following in addition to the above symptoms: restlessness, decreased energy, poor concentration, irritation, nervous tension, and insomnia. Beck Anxiety Inventory, Hamilton Anxiety and Depression Scale, Hospital Anxiety and Depression Scale, and the General Health Questionnaire have also been used for the study of post-stroke anxiety.

The prevalence of post-stroke anxiety, with or without PSD, is higher in hospital settings (acute stroke patients: 28, 15–17, and 3–13%, respectively; stroke survivors: 24, 6–17, and 3–11%, respectively) than in community studies (11, 8, and 1–2%, respectively). While one study showed that the prevalence of post-stroke anxiety decreased over time (33% at 3 months, 18% at 2 years), another study reported no such changes over 3 years after stroke. Post-stroke anxiety tends to last longer when it is associated with PSD. A recent systematic review involving 39 cohorts and 4,706 patients showed that 24% of patients with stroke had anxiety symptoms and 18% had an anxiety disorder in the first 5 years after stroke.

Because early-onset anxiety is more often associated with previous psychiatric disorders than late-onset anxiety, it has been proposed that early-onset anxiety may be a recurrence/exacerbation of a pre-stroke generalized anxiety disorder.

Although post-stroke anxiety by itself does not influence functional or cognitive recovery, it is associated with worse social functioning and quality of life. In a systematic review, the quality of life was negatively correlated with anxiety in four of five cohorts. Patients with post-stroke anxiety and PSD were worse in activities of daily living at 1- and 2-year follow-ups than patients with post-stroke anxiety alone.

Factors associated with post-stroke anxiety
Post-stroke anxiety is closely associated with PSD. Early studies proposed that following left hemispheric strokes, post-stroke anxiety with PSD is associated with cortical infarcts. On the other hand, following right hemispheric strokes, post-stroke anxiety without PSD is associated with posterior infarcts. However, a recent meta-analysis showed that there is no association between post-stroke anxiety and lesion location. Furthermore, no associations were observed with age and sex. Thus, the factors associated with anxiety in patients with stroke without PSD remain unknown.

Treatment
Antidepressant/antianxiety drugs alone or with psycho-behavioral therapy may reduce anxiety symptoms. However, because there are no randomized, placebo-controlled trials, there is not enough evidence regarding the management of post-stroke anxiety.
Emotional incontinence

Prevalence and characteristics

Since Wilson described patients with uncontrollable outbursts of involuntary laughing or crying as having “pathologic laughing and crying”\(^1\), these abnormal emotional displays have been described using a variety of terminologies: pseudobulbar affect, emotionalism, lability of mood, emotional incontinence, and involuntary emotional expression disorder.\(^2\)

Typically, patients show excessive and inappropriate crying or laughing without apparent motivating stimuli, or in response to stimuli that would not normally evoke such responses. The episodes are sudden, episodic, and uncontrollable. Although early reports emphasized the importance of these incongruent or contradictory emotional stimuli, and the “unheralded”, “uncontrollable” nature of symptoms,\(^3\) recent studies have found that symptoms are more often triggered by appropriate and congruent stimuli.\(^4,5\) Although some authors have distinguished strict pathological laughing and crying from milder emotional lability,\(^6\) more recent studies\(^6,7\) have reported that these two conditions differ in a quantitative rather than a qualitative way. With this consideration, we will use the broad term post-stroke emotional incontinence (PSEI) in this article.

The most frequently used diagnostic criteria are those of House,\(^8\) followed by those from Kim.\(^9\) In the acute/subacute stage of stroke, PSEI prevalence has been reported to vary from 6% to 34%\(^1,6-7\). The heterogeneous results are due to different diagnostic criteria, the timing of assessment, and characteristics of study populations. There have been few studies that examined the longitudinal course of PSEI. One report indicates that the prevalence of PSEI is 15% one month post-stroke, 21% at six months post-stroke, and 11% at twelve months post-stroke.\(^6\)

Factors and lesion locations associated with PSEI

Severe motor and neurologic dysfunction\(^6,7\), lesion location\(^1,6,7\), and the presence of depression\(^1,6,8\) are reported to be related to PSEI. We reported that lesion location (subcortical area) is the only factor associated with PSEI at the time of admission, whereas functional status, serotonin polymorphisms, and low social support were related to PSEI at three months post-stroke.\(^9\)

Studies using computed tomography and magnetic resonance imaging have shown that lenticulocapsular\(^7,10\) and brainstem lesions\(^7\) are closely related to PSEI. We studied 148 patients with unilateral strokes who were identified using computed tomography and magnetic resonance imaging and found that the anterior-cortex-internal capsule/basal ganglia-ventral brainstem circuitry is closely related to PSEI.\(^1\) Patients with lesions in the thalamus or cerebellum also occasionally exhibited PSEI. Although this lesion location is similar to that producing PSD, PSEI seems to be more closely related to subcortical (basal ganglia and pontine) lesions.\(^1\)

Pathogenesis

Wilson proposed that pathological crying and laughing is caused by the release (or disinhibition) of a brainstem fasciculostriate control center for emotional expression secondary to lesions of descending regulatory pathways.\(^7,11,12\) Previous studies have described patients presenting with PSEI due to lesions of the ponto-cerebellar pathway, and hypothesized that the cerebellum may play a modulatory role and adjust the execution of laughing or crying to cognitive and situational contexts.\(^7,11,12\) Rabins and Archinegas\(^13\) suggested that a complex cortico-limbic subcortical-thalamic-ponto-cerebellar system contributes to the expression of emotions, and any deficit in this system may lead to PSEI.

Neuroanatomical lesion studies suggest the involvement of serotonergic fibers,\(^14-16\) that ascends from the brainstem raphe nuclei to limbic forebrain structures and then project through the basal ganglia to the frontal cortex. Furthermore, serotonin transporter binding ratios in the midbrain and pons regions are lower in patients with stroke with PSEI than in those without PSEI.\(^17\) Finally, serotonin gene polymorphisms were found to be related to the development of PSEI.\(^18,19\)

Other neurotransmitters that may also be involved include dopamine and glutamate, which may have roles in regulating the influence of the motor cortex on the brainstem laughing/crying center.\(^18-20\) The balance between glutamatergic excitation and inhibition is in turn modulated by other neurotransmitter systems, such as dopamine, serotonin, acetylcholine, and sigma receptor systems.\(^21\) Non-competitive glutamate receptor antagonists, such as dextromethorphan stabilize glutamatergic neurotransmission,\(^22\) and have been found to be effective in the treatment of pathological laughing and crying in amyotrophic lateral sclerosis\(^23\) and multiple sclerosis,\(^24\) perhaps due to their effect on sigma-1 receptors. As activation of sigma-1 receptor agonists increases the serotonergic function of the dorsal raphe nucleus,\(^25\) dextromethorphan may also modulate the serotonergic system.

Treatment

A recent Cochrane review confirmed that SSRIs are effective in reducing the frequency and severity of PSEI.\(^25\) In five randomized controlled trials,\(^26-30\) SSRI administration was effective in alleviating PSEI. In addition, two randomized controlled trials have shown that tricyclic antidepressants are effective in treating PSEI.\(^31,32\) In the author’s view, SSRIs should be the first option for PSEI treatment, because they are better tolerated in stroke pa-
tients and more promptly reduce PSEI symptoms than tricyclic antidepressants.

There have been small studies that have used the selective adrenergic receptor inhibitors reboxetine,97 venlafaxine,98 mirtazapine,99 and lamotrigine.100 The mechanisms of action of these agents may involve the direct or indirect augmentation of serotonergic function. As discussed earlier, levodopa and amantadine may be effective in treating PSEI. Due to limited data, these selective adrenergic receptor inhibitors and dopaminergic drugs are currently reserved for patients who fail to respond to SSRIs.99 Dextromethorphan/quinidine (Nuedexta®, Avanir) is another potentially useful drug for the treatment of PSEI.105,106 Dextromethorphan is a sigma-1 receptor agonist, and adding quinidine sulfate increases the bioavailability of dextromethorphan.

**Post-stroke aggression and anger proneness**

Symptom characteristics and prevalence

Stroke patients may show aggressive behaviors including hitting or hurting others, kicking, biting, grabbing, pushing, throwing objects, etc. Their verbal behavior also includes cursing, screaming, making noises, hostile muttering, etc. This overt aggression is observed usually during the acute stage in patients. However, simple anger-proneness or inability to control anger and aggression is a much more commonly observed symptom. Patients become more irritable, impulsive, hostile, and less tolerable. They easily anger at their spouses and other family members regarding trivial matters.101 Therefore, these symptoms may be described as post-stroke anger proneness (PSAP).104

The PSAP has been studied using various tools, such as the Spielberger Trait Anger Scale, Present State Examination, NEO Personality Inventory Revised, and the Emotional Behavior Index.103-106 PSAP is found to be present in 15-35% of patients during the acute stage102,103,105,106 and in 32% of patients in the subacute stage.101 Although these results are not comparable due to different study settings and the different diagnostic tools used, we can at least conclude that anger proneness or aggressiveness is fairly common during both the acute and the subacute stages of stroke.

Associated factors, lesion locations, and pathophysiology

Studies have shown that motor dysfunction, dysarthria, high National Institute of Health Stroke Scale scores, previous stroke, premorbid neuroticism personality trait, history of depression, and low monoamine oxidase A activity are related to PSAP.101,103,104,106 Kim et al.101 emphasized that PSAP is more closely associated with PSEI than PSD and that the distribution of lesion locations associated with PSAP is similar to that of lesions associated with PSEI (fronto-lenticulocapsular-pontine base area).

Therefore, similar to PSEI, serotonergic dysfunction seems to play a role in the development of PSAP. Because PSAP is also associated with severe neurologic dysfunction, depression, and a previous history of stroke, some of the patients' anger may be a manifestation of depression or frustration. Thus, PSAP may be a multi-factorial phenomenon related to reactive behavioral changes associated with functional deficits and repeated strokes, serotonergic dysfunction due to brain damage, or genetic polymorphisms involving monoamine oxidase A.101

**Treatment**

SSRIs such as fluoxetine107 and citalopram108 are of benefit in the treatment of aggressive behavior in patients with personality disorder or dementia. Beta adrenergic antagonists109 and lithium110 may reduce aggressiveness in patients with brain injury. However, clinical trials in patients with stroke are very rare. In our double-blinded study, anger scores were significantly reduced after fluoxetine therapy in patients with subacute stroke.111 In the author's more recent study involving 478 patients, escitalopram was effective in the prevention of anger-proneness when administered during the acute stage.30

**Post-stroke fatigue**

Symptom characteristics and prevalence

Staub and Bogousslavsky111 defined fatigue in stroke patients as ‘a feeling of early exhaustion developing during mental activity, with weariness, lack of energy, and aversion to effort’. Fatigue can be further distinguished by its onset: fatigue during the acute stage vs. chronic, persistent fatigue. It can also be classified based on different constructs: exertion vs. mental fatigue.112

Although there is no fatigue scale that fully considers the complex nature of PSF, several instruments have been developed to measure PSF: the Fatigue Assessment Scale,113 the Fatigue Impact Scale,114 the Checklist of Individual Strength,115 the Visual Analogue Scale,116,117 the Chalder fatigue scale,118 the Multi-dimensional Fatigue Symptom Inventory,119 and the Fatigue Severity Scale.120,121

The prevalence of PSF ranges from 23% to 75%.112 This wide range is attributable to differences in the definition of PSF, the time elapsed since stroke, and the characteristics of patients. In a systematic review of nine longitudinal cohort studies, the authors reported that the prevalence of fatigue decreased with time after stroke in seven studies, but increased in two studies.123
Factors associated with post-stroke fatigue

Neurologic deficit is one of the most important factors related to PSF. However, the association may at least in part be attributed to associated depression. Studies have shown that the significant association between disability and PSF in the subacute state is lost after controlling for the effects of depression during the chronic stage. Medical co-morbidities such as hypertension, medications such as sedative drugs or antidepressants, decreased appetite, and sleep disturbances may result in PSF. In addition, post-stroke pain, and pre-stroke fatigue have been found to be associated with PSF.

Although patients with PSF are often depressed, many PSF patients do not have depression. Although one study reported an association between PSF and suicidality, PSF patients rarely express worthlessness and hopelessness. The impact of depression on PSF may differ according to the stage of stroke. While neurologic disability leads to exer-tional fatigue during the early stage of stroke, depression seems to play a more important role in chronic and mental fatigue. Thus, depression may be a factor in prolonged fatigue. Impairments in some domains of cognition, such as attention deficits, slow mental processing, and memory dysfunction, seems to be associated with mental fatigue.

Studies have shown that PSF is related to damage to the medial prefrontal cortex, basal ganglia, and the brainstem/thalamocortical reticular formation. This suggests that alterations in neurotransmitters such as dopamine or adrenaline may lead to PSF. However, more recent MRI-based studies have found no association between PSF and lesion location. Chronic inflammation and altered immune responses after stroke may also be involved in PSF.

Treatment

A double-blinded placebo-controlled trial involving 83 patients with PSF showed that fluoxetine was not effective in improving PSF. Another study showed that duloxetine, citalopram, and sertraline did not relieve PSF. Thus, SSRIs may not be effective for PSF. Modafinil, a drug originally used for patients with hypersomnia or narcolepsy, was used in a recent randomized, placebo-controlled trial. Forty-one patients were treated with either 400 mg modafinil or placebo. There was no difference in the primary outcomes or Multidimensional Fatigue Inventory–20 general fatigue scores 90 days post-stroke. However, modafinil improved PSF, as measured by the Fatigue Severity Score, a secondary outcome (P = 0.02). Thus, more studies are needed to confirm the efficacy of modafinil as a treatment for PSF. The neurobiochemical effects of modafinil remain unclear. It may affect dopamine and norepinephrine transporters. It is also known to have some effects on the serotonin, glutamate, orexin, and histamine systems.

Summary

Post-stroke mood and emotional disturbances are common and manifest in diverse manners. The phenomenology, predicting factors, pathophysiology, and response to pharmacological treatments are different, although there are also factors that are in common. PSD appears to be associated with complex pathophysiological mechanisms involving both psychological/psychiatric problems associated with patients’ functional deficits and neurochemical changes secondary to brain damage. Therefore, although antidepressants, and especially SSRIs, are considered to be the management options of choice, their benefits are not robust. It remains uncertain whether pharmacological treatment in stroke patients is needed to prevent PSD or perhaps to improve neurological outcomes.

PSEI is more closely associated with lesion location and consequent alterations in neurotransmitters, notably serotonin. Thus, PSEI tends to respond more to SSRIs compared to PSD. Although PSAP is also a complex phenomenon, it seems to have better responsiveness to SSRIs than PSD. PSF is a common and disabling symptom. Although PSF is closely associated with PSD, it is also causally related to multiple factors, including functional impairment, co-morbid diseases, and perhaps, multiple neurotransmitter changes. Thus, the benefits of pharmacological therapy are unproven, and treatment may have to be individualized according to the causative factors present in each patient. Adrenergic/dopaminergic drugs such as modafinil may be used in some patients.

Recognizing these emotional disturbances is important because they are often treatable. Proper management may improve patients’ quality of life in a prolonged manner, even after the cessation of treatment. Undoubtedly, more research is needed to improve the management of post-stroke mood and emotional disturbances.

References

1. Kim JS, Choi-Kwon S. Poststroke depression and emotional incontinence: Correlation with lesion location. Neurology 2000;54:1805-1810.
2. Kim JS, Choi-Kwon S, Kwon SU, Lee HJ, Park KA, Seo YS. Factors affecting the quality of life after ischemic stroke: young versus old patients. J Clin Neurol 2005;1:59-68.
3. Choi-Kwon S, Kim HS, Kwon SU, Kim JS. Factors affecting the
burden on caregivers of stroke survivors in South Korea. Arch Phys Med Rehabil 2005;86:1043-1048.
4. Kotila M, Numminen H, Waltimo O, Kaste M. Post-stroke depression and functional recovery in a population-based stroke register. The Finnstroke study. Eur J Neurol 1999;6:309-312.
5. van de Weg FB, Kuijk DJ, Lankhorst GJ. Post-stroke depression and functional outcome: a cohort study investigating the influence of depression on functional recovery from stroke. Clin Rehabil 1999;13:268-272.
6. Paolucci S, Antonucci G, Pratesi L, Traballesi M, Grasso MG, Lubich S. Poststroke depression and its role in rehabilitation of inpatients. Arch Phys Med Rehabil 1999;80:985-990.
7. Loong CK, Kenneth NK, Paulin ST. Post-stroke depression: Outcome following rehabilitation. Aust N Z J Psychiatry 1995;29:609-614.
8. Gillen R, Tenen H, McKee TE, Gernert-Dott P, Affleck G. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil 2001;82:1645-1649.
9. Liman TG, Heuschmann PU, Endres M, Floel A, Schwab S, Kolominsky-Rabas PL. Impact of low mini-mental status on health outcome up to 5 years after stroke: the elrangen stroke project. J Neurol 2012;259:1125-1130.
10. Burvill PW, Johnson GA, Jamrozik KD, Anderson CS, Stewart-Wynne EG, Chakera TM. Anxiety disorders after stroke: results from the Perth community stroke study. Br J Psychiatry 1995;166:328-332.
11. Townend BS, Whyte S, Desborough T, Crimmins D, Markus R, Levi C, et al. Longitudinal prevalence and determinants of early mood disorder post-stroke. J Clin Neurosci 2007;14:429-434.
12. Choi-Kwon S, Han SW, Kwon SU, Kim JS. Poststroke fatigue: characteristics and related factors. Cerebrovasc Dis 2005;19:84-90.
13. Naess H, Nyland HI, Thomassen L, Aarseth J, Myhr KM. Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovasc Dis 2005;20:245-250.
14. Radman N, Staub F, Aboulafia-Brakha T, Berney A, Bogousslavsky J, Annoni JM. Poststroke fatigue following minor infarcts: A prospective study. Neurology 2012;79:1422-1427.
15. Pihlaja R, Uimonen J, Mustanaja S, Tatlisumak T, Poutiainen E. Post-stroke fatigue is associated with impaired processing speed and memory functions in first-ever stroke patients. J Psychosom Res 2014;77:380-384.
16. Andersen G, Christensen D, Kirkevold M, Johnsen SP. Post-stroke fatigue and return to work: a 2-year follow-up. Acta Neurol Scand 2012;125:248-253.
17. Noh SM, Chung SJ, Kim KK, Kang DW, Lim YM, Kwon SU, et al. Emotional disturbance in CADASIL: its impact on quality of life and caregiver burden. Cerebrovasc Dis 2014;37:188-194.
18. de Coster L, Leentjens AF, Lodder J, Verhey FR. The sensitivity of somatic symptoms in post-stroke depression: a discriminant analytic approach. Int J Geriatr Psychiatry 2005;20:358-362.
19. Hackett ML, Kohler S, O’Brien JT, Mead GE. Neuropsychiatric outcomes of stroke. Lancet Neurol 2014;13:525-534.
20. Dennis M, O’Rourke S, Lewis S, Sharpe M, Warlow C. Emotional outcomes after stroke: factors associated with poor outcome. J Neurol Neurosurg Psychiatry 2000;68:47-52.
21. Gainotti G, Marra C. Determinants and consequences of post-stroke depression. Curr Opin Neurol 2002;15:85-89.
22. Morrison V, Pollard B, Johnston M, MacWalter R. Anxiety and depression 3 years following stroke: demographic, clinical, and psychological predictors. J Psychosom Res 2005;59:209-213.
23. Nys GM, van Zandvoort MJ, van der Worp HB, de Haan EH, de Kort PL, Kappelle LJ. Early depressive symptoms after stroke: neuropsychological correlates and lesion characteristics. J Neurol Sci 2005;228:27-33.
24. Caeiro L, Ferro JM, Santos CO, Figueira ML. Depression in acute stroke. J Psychiatry Neurosci 2006;31:377-383.
25. Linden T, Blomstrand C, Skoog I. Depressive disorders after 20 months in elderly stroke patients: a case-control study. Stroke 2007;38:1860-1863.
26. Ferro JM, Caeiro L, Santos C. Poststroke emotional and behavioral impairment: a narrative review. Cerebrovasc Dis 2009;27 Suppl 1:197-203.
27. Hackett ML, Pickles K. Part i: Frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke 2014;9:1017-1025.
28. Robinson RG, Spalletta G. Poststroke depression: a review. Can J Psychiatry 2010;55:341-349.
29. Astrom M, Adolfsson R, Asplund K. Major depression in stroke patients. A 3-year longitudinal study. Stroke 1993;24:976-982.
30. Kim JS Lee EJ, Chang DI, Park JH, Ahn SH, Cha JK, et al. Efficacy of early administration of escitalopram on post-stroke depressive/emotional symptoms and neurologic dysfunction: a multicenter, double blind, randomized, placebo-controlled study. Lancet Psychiatry 2016: in press.
31. Kutluabaev MA, Hackett ML. Part ii: Predictors of depression after stroke and impact of depression on stroke outcome: an updated systematic review of observational studies. Int J Stroke 2014;9:1026-1036.
32. Aben I, Denollet J, Lousberg R, Verhey F, Wojciechowski F, Honig A. Personality and vulnerability to depression in stroke
patients: a 1-year prospective follow-up study. Stroke 2002; 33:2391–2395.

33. Starkstein SE, Robinson RG, Price TR. Comparison of cortical and subcortical lesions in the production of poststroke mood disorders. Brain 1987;110:1045–1059.

34. Bhogal SK, Teasell R, Foley N, Speechley M. Lesion location and poststroke depression: systematic review of the methodological limitations in the literature. Stroke 2004;35:794–802.

35. Morris PL, Robinson RG, Raphael B, Hopwood MJ. Lesion location and poststroke depression. J Neuropsychiatry Clin Neurosci 1996;8:399–403.

36. Carson AJ, MacHale S, Allen K, Lawrie SM, Dennis M, House A, et al. Depression after stroke and lesion location: A systematic review. Lancet 2000;356:122–126.

37. Shimoda K, Robinson RG. The relationship between poststroke depression and lesion location in long-term follow-up. Biol Psychiatry 1999;45:187–192.

38. Narushima K, Kosier JT, Robinson RG. A reappraisal of poststroke depression, intra- and inter-hemispheric lesion location using meta-analysis. J Neuropsychiatry Clin Neurosci 2003;15:422–430.

39. Barker-Collo SL. Depression and anxiety 3 months post stroke: Prevalence and correlates. Arch Clin Neuropsychol 2007;22: 519–531.

40. Brodaty H, Withall A, Altendorf A, Sachdev PS. Rates of depression at 3 and 15 months poststroke and their relationship with cognitive decline: the Sydney Stroke Study. Am J Geriatr Psychiatry 2007;15:477–486.

41. Carota A, Berney A, Aybek S, Iaria G, Staub F, Ghika-Schmid F, et al. A prospective study of predictors of poststroke depression. Neurology 2005;64:428–433.

42. Robinson RG, Jorge RE. Post-stroke depression: a review. Am J Psychiatry 2016;173:221–231.

43. Luijendijk HJ, Stricker BH, Wieberdink RG, Koudstaal PJ, Hofman A, Breteler MM, et al. Transient ischemic attack and incident depression. Stroke 2011;42:1857–1861.

44. Hackett ML, Anderson CS, House A, Halteh C. Interventions for preventing depression after stroke. Cochrane Database Syst Rev 2008:CD003689.

45. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2008:CD003437.

46. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 2008;299:2391–2400.

47. Tsai CS, Wu CL, Chou SY, Tsang HY, Hung TH, Su JA. Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke: a double-blind randomized placebo-controlled trial. Int Clin Psychopharmacol 2011;26:263–267.

48. Quinn TJ, Paolucci S, Sunnerhagen KS, Sivenius J, Walker MF, Toni D, et al. Evidence-based stroke rehabilitation: an expanded guidance document from the European stroke organisation (eso) guidelines for management of ischaemic stroke and transient ischaemic attack 2008. J Rehabil Med 2009;41: 99–111.

49. Miller EL, Murray L, Richards L, Zorowitz RD, Bakas T, Clark P, et al. Comprehensive overview of nursing and interdisciplin- ary rehabilitation care of the stroke patient: a scientific statement from the American heart association. Stroke 2010;41: 2402–2448.

50. Castillo CS, Schultz SK, Robinson RG. Clinical correlates of early-onset and late-onset poststroke generalized anxiety. Am J Psychiatry 1995;152:1174–1179.

51. Schultz SK, Castillo CS, Kosier JT, Robinson RG. Generalized anxiety and depression. Assessment over 2 years after stroke. Am J Geriatr Psychiatry 1997;5:229–237.

52. Astrom M. Generalized anxiety disorder in stroke patients. A 3-year longitudinal study. Stroke 1996;27:270–275.

53. Campbell Burton CA, Murray J, Holmes J, Astin F, Greenwood D, Knapp P. Frequency of anxiety after stroke: a systematic review and meta-analysis of observational studies. Int J Stroke 2013;8:545–559.

54. Shimoda K, Robinson RG. Effects of anxiety disorder on impairment and recovery from stroke. J Neuropsychiatry Clin Neurosci 1998;10:34–40.

55. Starkstein SE, Cohen BS, Fedoroff P, Parikh RM, Price TR, Robinson RG. Relationship between anxiety disorders and depressive disorders in patients with cerebrovascular injury. Arch Gen Psychiatry 1990;47:246–251.

56. Campbell Burton CA, Holmes J, Murray J, Gillespie D, Lightbody CE, Watkins CL, et al. Interventions for treating anxiety after stroke. Cochrane Database Syst Rev 2011:CD008860.

57. Wilson SA. Original papers: Some problems in neurology. J Neurol Psychiatr 1924;4:299–333.

58. Cummings JL, Arciniegas DB, Brooks BR, Herrndon RM, Lauterbach EC, Pioro EP, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr 2006;11:1–7.

59. Poehl K. Pathophysiology of emotional disorders associated with brain damage. In:Vinken PJ, Bruyn GW, ed. Handbook of Clinical Neurology. New York: Elsevier 1969:343–367.

60. House A, Dennis M, Molyneux A, Warlow C, Hawton K. Emotionalism after stroke. BMJ 1989;298:991–994.

61. Allman P, Hope T, Fairburn CG. Crying following stroke. A report on 30 cases. Gen Hosp Psychiatry 1992;14:315–321.
62. Nieuwenhuis-Mark RE, van Hoek A, Vingerhoets A. Understanding excessive crying in neurologic disorders: nature, pathophysiology, assessment, consequences, and treatment. Cogn Behav Neurol 2008;21:111-123.
63. Morris PL, Robinson RG, Raphael B. Emotional lability after stroke. Aust N Z J Psychiatry 1993;27:601-605.
64. MacHale SM, Cavanagh JT, Bennie J, Carroll S, Goodwin GM, Lawrie SM. Diurnal variation of adrenocortical activity in chronic fatigue syndrome. Neuropsychobiology 1998;38:213-217.
65. Calvert T, Knapp P, House A. Psychological associations with emotionalism after stroke. J Neurol Neurosurg Psychiatry 1998;65:928-929.
66. Kim JS. Post-stroke emotional incontinence after small lenticulocapsular stroke: correlation with lesion location. J Neurol 2002;249:805-810.
67. Tang WK, Chan SS, Chiu HF, Ungvari GS, Wong KS, Kwok TC. Emotional incontinence in chinese stroke patients—diagnosis, frequency, and clinical and radiological correlates. J Neuro 2004;251:865-869.
68. Tang WK, Chen YK, Lu JY, Mok VC, Xiang YT, Ungvari GS, et al. Microbleeds and post-stroke emotional lability. J Neurol Neurosurg Psychiatry 2009;80:1082-1086.
69. Kim JM, Stewart R, Kang HJ, Bae KY, Kim SW, Shin IS, et al. Associations of serotonergic genes with poststroke emotional incontinence. Int J Geriatr Psychiatry 2012;27:799-806.
70. Choi-Kwon S, Han K, Choi S, Suh M, Kim YJ, Song H, et al. Poststroke depression and emotional incontinence: factors related to acute and subacute stages. Neurology 2012;78:1130-1137.
71. Ceccaldi M, Milandre L. A transient fit of laughter as the inaugural symptom of capsular-thalamic infarction. Neurology 1994;44:1762.
72. Kim JS. Pathologic laughter after unilateral stroke. J Neurol Sci 1997;148:121-125.
73. Parvizi J, Anderson SW, Martin CO, Damasio H, Damasio AR. Pathological laughter and crying: a link to the cerebellum. Brain 2001;124:1708-1719.
74. Pollack IF, Polinco P, Albright AL, Towbin R, Fitz C. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery 1995;37:885-893.
75. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 1998;121 (Pt 4):561-579.
76. Levisohn L, Cronin-Golomb A, Schmahmann JD. Neuropsychological consequences of cerebellar tumor resection in children: cerebellar cognitive affective syndrome in a pediatric population. Brain 2000;123:1041-1050.
77. Parvizi J, Schiffer R. Exaggerated crying and tremor with a cerebellar cyst. J Neuropsychiatry Clin Neurosci 2007;19:187-190.
78. Parvizi J, Joseph J, Press DZ, Schmahmann JD. Pathological laughter and crying in patients with multiple system atrophy-cerebellar type. Mov Disord 2007;22:798-803.
79. Rabins PV, Arciniegas DB. Pathophysiology of involuntary emotional expression disorder. CNS Spectr 2007;12:17-22.
80. Choi-Kwon S, Kim JS. Poststroke emotional incontinence and decreased sexual activity. Cerebrovasc Dis 2002;13:31-37.
81. Andersen G, Ingeman-Nielsen M, Vestergaard K, Riis JO. Patho-anatomic correlation between poststroke pathological crying and damage to brain areas involved in serotonergic neurotransmission. Stroke 1994;25:1050-1052.
82. Murai T, Barthel H, Berrouschot J, Sorger D, von Cramon DY, Muller U. Neuroimaging of serotonin transporters in poststroke pathological crying. Psychiatry Res 2003;123:207-211.
83. Wolf JK, Santana HB, Thorpy M. Treatment of “emotional incontinence” with levodopa. Neurology 1979;29:1435-1436.
84. Udaka F, Yamao S, Nagata H, Nakamura S, Kameyama M. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984;41:1095-1096.
85. Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-1370.
86. Rogawski MA. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents—toward an understanding of their favorable tolerability. Amino Acids 2000;19:133-149.
87. Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006;59:780-787.
88. Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005;97:317-336.
89. Hackett ML, Yang M, Anderson CS, Horrocks JA, House A. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database Syst Rev 2010;CD003690.
90. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993;342:837-839.
91. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotional disturbances. J Psychol Med 1999;32:1-9.
92. Burns A, Russell E, Stratton-Powell H, Tyrell P, O’Neill P, Baldwin R. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999;14:681-685.
AM, Lundmark J, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. *J Clin Psychiatry* 2005;66:708-716.

94. Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. *Stroke* 2006;37:156-161.

95. Ohkawa S, Mori E, Yamadori A. Treatment of pathological laughing with amitriptyline. *Rinsho Shinkeigaku* 1989;29:1183-1185.

96. Robinson RG, Parikh RM, Lipsky JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. *Am J Psychiatry* 1993;150:286-293.

97. Molander M, Andersen G. Inhibition of selective noradrenergic reuptake as treatment of pathological laughter. *J Clin Psychopharmacol* 2007;27:108-110.

98. Smith AG, Montealegre-Orjuela M, Douglas JE, Jenkins EA. Venlafaxine for pathological crying after stroke. *J Clin Psychiatry* 2003;64:731-732.

99. Kim SW, Shin IS, Kim JM, Lim SY, Yang SJ, Yoon JS. Mirtazapine treatment for post-stroke patho-behavioral and psychological symptoms: a three-month follow-up study in Perth, western Australia. *Psychogeriatr* 2009;21:1063-1071.

100. Ramasubbu R. Lamotrigine treatment for post-stroke pathological laughing and crying. *Clin Neuropharmacol* 2003;26:233-235.

101. Kim JS, Choi S, Kwon SU, Seo YS. Inability to control anger or aggression after stroke. *Neurology* 2002;58:1106-1108.

102. Chan KL, Campayo A, Moser DJ, Arndt S, Robinson RG. Aggressive behavior in patients with stroke: association with psychopathology and results of antidepressant treatment on aggression. *Arch Phys Med Rehabil* 2006;87:793-798.

103. Aybek S, Carota A, Ghika-Schmid F, Berney A, Melle GV, Guex P, et al. Emotional behavior in acute stroke: the lausanne emotion in stroke study. *Cogn Behav Neurol* 2005;18:37-44.

104. Greenop KR, Almeida OP, Hankey GJ, van Bockxmeer F, Lautenschlager NT. Premorbid personality traits are associated with post-stroke behavioral and psychological symptoms: a three-month follow-up study in Perth, western Australia. *Int Psychogeriatr* 2009;21:1063-1071.

105. Santos CO, Caeiro L, Ferro JM, Albuquerque R, Luisa Figueira M. Anger, hostility and aggression in the first days of acute stroke. *Eur J Neurol* 2006;13:351-358.

106. Choi-Kwon S, Han K, Cho KH, Choi S, Suh M, Nah HW, et al. Factors associated with post-stroke anger proneness in ischemic stroke patients. *Eur J Neurol* 2013;20:1305-1310.

107. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. *Arch Gen Psychiatry* 1997;54:1081-1088.

108. Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. *Am J Geriatr Psychiatry* 2007;15:942-952.

109. Fleminger S, Greenwood RJ, Oliver DL. Pharmacological management for agitation and aggression in people with acquired brain injury. *Cochrane Database Syst Rev* 2006:CD003299.

110. Glenn MB, Wroblewski B, Parziale J, Levine L, Whyte J, Rosenthal M. Lithium carbonate for aggressive behavior or affective instability in ten brain-injured patients. *Am J Phys Med Rehabil* 1989;68:221-226.

111. Staub F, Bogousslavsky J. Fatigue after stroke: a major but neglected issue. *Cerebrovasc Dis* 2001;12:75-81.

112. Choi-Kwon S, Kim JS. Poststroke fatigue: an emerging, critical issue in stroke medicine. *Int J Stroke* 2011;6:328-336.

113. Smith OR, van den Broek KC, Renkens M, Deenollet J. Comparison of fatigue levels in patients with stroke and patients with end-stage heart failure: application of the fatigue assessment scale. *J Am Geriatr Soc* 2008;56:1915-1919.

114. Inglese JL, Eskes GA, Phillips SJ. Fatigue after stroke. *Arch Phys Med Rehabil* 1999;80:173-178.

115. van der Werf SP, van den Broek HL, Anten HW, Bleijenberg G. Experience of severe fatigue long after stroke and its relation to depressive symptoms and disease characteristics. *Eur Neurol* 2001;45:28-33.

116. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine is not effective in the treatment of post-stroke fatigue: a double-blind, placebo-controlled study. *Cerebrovasc Dis* 2007;23:103-108.

117. Michael KM, Allen JK, Macko RF. Fatigue after stroke: Relationship to mobility, fitness, ambulatory activity, social support, and falls efficacy. *Rehabil Nurs* 2006;31:210-217.

118. Winward C, Sackley C, Metha Z, Rothwell PM. A population-based study of the prevalence of fatigue after transient ischemic attack and minor stroke. *Stroke* 2009;40:757-761.

119. Christensen D, Johnsen SP, Watt T, Harder I, Kirkevold M, Andersen G. Dimensions of post-stroke fatigue: a two-year follow-up study. *Cerebrovasc Dis* 2008;26:134-141.

120. van de Port IG, Kwakkel G, Schepers VP, Heinemans CT, Lindeboom J, Reiners G. Fatigue and health-related quality of life in chronic stroke? *Cerebrovasc Dis* 2007;23:40-45.

121. Tang WK, Chen YK, Mok V, Chu WC, Ungvari GS, Ahuja AT, et al. Acute basal ganglia infarcts in poststroke fatigue: an MRI study. *J Neurol* 2010;257:178-182.
122. Lerdal A, Bakken LN, Rasmussen EF, Beiermann C, Ryen S, Pynten S, et al. Physical impairment, depressive symptoms and pre-stroke fatigue are related to fatigue in the acute phase after stroke. Disabil Rehabil 2011;33:334-342.

123. Duncan F, Wu S, Mead GE. Frequency and natural history of fatigue after stroke: a systematic review of longitudinal studies. J Psychosom Res 2012;73:18-27.

124. Glader EL, Stegmayr B, Asplund K. Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke 2002;33:1327-1333.

125. Appelros P. Prevalence and predictors of pain and fatigue after stroke: a population-based study. Int J Rehabil Res 2006;29:329-333.

126. Snaphaan L, van der Werf S, de Leeuw FE. Time course and risk factors of post-stroke fatigue: a prospective cohort study. Eur J Neurol 2011;18:611-617.

127. Harbison JA, Walsh S, Kenny RA. Hypertension and daytime hypotension found on ambulatory blood pressure is associated with fatigue following stroke and TIA. QJM 2009;102:109-115.

128. Wang SS, Wang JJ, Wang PX, Chen R. Determinants of fatigue after first-ever ischemic stroke during acute phase. PLoS ONE 2014;9:e110037.

129. Naess H, Lunde L, Brogger J. The triad of pain, fatigue and depression among stroke patients on long-term follow-up: the Bergen stroke study. J Neurol 2011;258:670-676.

130. Naess H, Lunde L, Brogger J, Waje-Andreassen U. Post-stroke pain on long-term follow-up: the Bergen stroke study. J Neurol 2010;257:1446-1452.

131. van de Port IG, Kwakkel G, Bruin M, Lindeman E. Determinants of depression in chronic stroke: a prospective cohort study. Disabil Rehabil 2007;29:353-358.

132. Hoang CL, Salle JY, Mandigout S, Hamonet J, Macian-Montoro F, Daviet JC. Physical factors associated with fatigue after stroke: an exploratory study. Top Stroke Rehabil 2012;19:369-376.

133. Duncan F, Greig C, Lewis S, Dennis M, MacLullich A, Sharpe M, et al. Clinically significant fatigue after stroke: a longitudinal cohort study. J Psychosom Res 2014;77:368-373.

134. Hubacher M, Calabrese P, Bassetti C, Carota A, Stocklin M, Penner IK. Assessment of post-stroke fatigue: the fatigue scale for motor and cognitive functions. Eur J Neurol 2012;19:1336-1338.

135. Jaracz K, Mielcarek L, Kozutski W. Clinical and psychological correlates of poststroke fatigue. Preliminary results. Neurol Neurochir Pol 2007;41:36-43.

136. Staub F, Annoni JM, Bogousslavsky J. Fatigue after stroke: a major problem in “non-disabling” stroke. Neural Plasticity 2012;2012:686425.

137. Naess H, Lunde L, Brogger J, Waje-Andreassen U. Post-stroke pain on long-term follow-up: the Bergen stroke study. J Neurol 2010;257:1446-1452.

138. Hoang CL, Salle JY, Mandigout S, Hamonet J, Macian-Montoro F, Daviet JC. Physical factors associated with fatigue after stroke: an exploratory study. Top Stroke Rehabil 2012;19:369-376.
152. Poulsen MB, Damgaard B, Zerahn B, Overgaard K, Rasmussen RS. Modafinil may alleviate poststroke fatigue: a randomized, placebo-controlled, double-blinded trial. Stroke 2015;46:3470-3477.

153. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006;67:554-566.

154. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovasc Dis 2008;26:266-271.